MRI contrast firm Epix files IPO

Article

Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa

Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa developer of targeted contrast agents, including MS-325, a gadolinium-basedagent for MR angiography of coronary and peripheral arteries.

Epix has licensed rights to MS-325 and other MRI vascular agentsin all countries except Japan to Mallinckrodt of St. Louis (SCAN10/9/96). MS-325 has entered phase I clinical trials, and proceedsfrom Epix's IPO will help fund that work and will be used forgeneral corporate purposes.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.